Sjogren's Syndrome Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Sjogren's syndrome Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Sjogren's syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Sjogren's Syndrome Research. Learn more about our innovative pipeline today! @ Sjogren's Syndrome Pipeline Outlook- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Sjogren's Syndrome Pipeline Report
• In July 2025, Novartis Pharmaceuticals announced a study is intended to assess safety, cellular kinetics and any early sign for efficacy of rapcabtagene autoleucel in participants with difficult-to-treat rheumatoid arthritis (D2T RA) and severe, refractory Sjogren's disease (srSjD) with organ involvement.
• In July 2025, Otsuka Pharmaceutical Development & Commercialization, Inc. announced a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
• In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD). This clinical development program for nipocalimab in SjD includes 2 identical double blind, placebo-controlled studies to evaluate the efficacy, safety, and tolerability of nipocalimab in participants greater than or equal to (>=) 18 years of age with moderate to severe SjD.
• In July 2025, Amgen organized a study will enroll 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity; Population 2 will include participants with moderate to severe subjective symptoms. This study will include 3 periods: screening (5 weeks), treatment period (48 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized to receive subcutaneous (SC) dose of HZN-1116 or placebo.
• DelveInsight's Sjogren's Syndrome pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Sjogren's Syndrome treatment.
• The leading Sjogren's Syndrome Companies such as Novartis, Amgen, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici and others.
• Promising Sjogren's Syndrome Pipeline Therapies such as Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib, Tirabrutinib, RO5459072 and others.

Stay informed about the cutting-edge advancements in Sjogren's Syndrome treatments. Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders Care @ Sjogren's Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sjogren's Syndrome Emerging Drugs Profile

• VAY736: Novartis
VAY736 (ianalumab) is a novel, intravenous, defucosylated, human IgG1/κ monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. The BAFF receptor is predominantly expressed on B cells and is critically involved in B cell maturation, activation, and survival. VAY736 targets the BAFF receptor and competitively inhibits BAFF binding to BAFF-R, thereby blocking BAFF-R-mediated signaling in B cells. It is also engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). The ADCC activity of ianalumab is greatly enhanced by eliminating fucose residues from the carbohydrate moiety attached to the Fc part of the antibody. The molecule is being developed by Novartis in partnership with MorphoSys as an antibody-based therapy. The drug is currently in Phase III clinical studies for the treatment of Sjögren's Syndrome (SS).

• Dazodalibep: Amgen
Dazodalibep (VIB4920) is a fusion protein developed by Horizon therapeutics, designed to bind to CD40L on activated T-cells, blocking their interaction with CD40-expressing B-cells. According to the company, this approach could inhibit the stimulation of dendritic cells and monocytes, thereby reducing the production of molecules that cause inflammation endemic to T- and B-cell-driven diseases. Currently, the drug is in the Phase III stage of its development for the treatment of Sjögren's Syndrome.

The Sjogren's Syndrome Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sjogren's Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sjogren's Syndrome Treatment.
• Sjogren's Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sjogren's Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sjogren's Syndrome market.

Learn more about Sjogren's Syndrome Drugs opportunities in our groundbreaking Sjogren's Syndrome research and development projects @ Sjogren's Syndrome Unmet Needs- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sjogren's Syndrome Companies
Novartis, Amgen, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici and others.

Sjogren's syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Sjogren's Syndrome Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Sjogren's Syndrome treatment by visiting our website. Stay informed about how we're transforming the future of Immunological and Autoimmune Disorders @ Sjogren's Syndrome Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Sjogren's Syndrome Pipeline Report
• Coverage- Global
• Sjogren's Syndrome Companies- Novartis, Amgen, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici and others.
• Sjogren's Syndrome Pipeline Therapies- Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib, Tirabrutinib, RO5459072 and others.
• Sjogren's Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Sjogren's Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Sjogren's Syndrome Pipeline on our website @ Sjogren's Syndrome Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of contents
1. Introduction
2. Executive Summary
3. Sjogren's syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sjogren's syndrome- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. VAY736: Novartis
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Product Name: Company Name
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Product Name: Company Name
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Sjogren's syndrome Key Companies
21. Sjogren's syndrome Key Products
22. Sjogren's syndrome- Unmet Needs
23. Sjogren's syndrome- Market Drivers and Barriers
24. Sjogren's syndrome- Future Perspectives and Conclusion
25. Sjogren's syndrome Analyst Views
26. Sjogren's syndrome Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.